These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 23873592)
1. In vitro tools for evaluating novel dosage forms of poorly soluble, weakly basic drugs: case example ketoconazole. Taupitz T; Dressman JB; Klein S J Pharm Sci; 2013 Oct; 102(10):3645-52. PubMed ID: 23873592 [TBL] [Abstract][Full Text] [Related]
2. Cyclodextrin-water soluble polymer ternary complexes enhance the solubility and dissolution behaviour of poorly soluble drugs. Case example: itraconazole. Taupitz T; Dressman JB; Buchanan CM; Klein S Eur J Pharm Biopharm; 2013 Apr; 83(3):378-87. PubMed ID: 23201048 [TBL] [Abstract][Full Text] [Related]
3. New formulation approaches to improve solubility and drug release from fixed dose combinations: case examples pioglitazone/glimepiride and ezetimibe/simvastatin. Taupitz T; Dressman JB; Klein S Eur J Pharm Biopharm; 2013 May; 84(1):208-18. PubMed ID: 23246797 [TBL] [Abstract][Full Text] [Related]
4. Application of a ternary HP-β-CD-complex approach to improve the dissolution performance of a poorly soluble weak acid under biorelevant conditions. Zoeller T; Dressman JB; Klein S Int J Pharm; 2012 Jul; 430(1-2):176-83. PubMed ID: 22531855 [TBL] [Abstract][Full Text] [Related]
5. Synergetic skin targeting effect of hydroxypropyl-β-cyclodextrin combined with microemulsion for ketoconazole. Che J; Wu Z; Shao W; Guo P; Lin Y; Pan W; Zeng W; Zhang G; Wu C; Xu Y Eur J Pharm Biopharm; 2015 Jun; 93():136-48. PubMed ID: 25845772 [TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo evaluation of oral tablet formulations prepared with ketoconazole and hydroxypropyl-beta-cyclodextrin. Taneri F; Ozcan I; Guneri T Drug Deliv; 2010 Apr; 17(3):152-7. PubMed ID: 20148713 [TBL] [Abstract][Full Text] [Related]
7. Assessment of Bioequivalence of Weak Base Formulations Under Various Dosing Conditions Using Physiologically Based Pharmacokinetic Simulations in Virtual Populations. Case Examples: Ketoconazole and Posaconazole. Cristofoletti R; Patel N; Dressman JB J Pharm Sci; 2017 Feb; 106(2):560-569. PubMed ID: 27865610 [TBL] [Abstract][Full Text] [Related]
8. Improved dissolution and absorption of ketoconazole in the presence of organic acids as pH-modifiers. Adachi M; Hinatsu Y; Kusamori K; Katsumi H; Sakane T; Nakatani M; Wada K; Yamamoto A Eur J Pharm Sci; 2015 Aug; 76():225-30. PubMed ID: 25988287 [TBL] [Abstract][Full Text] [Related]
9. Comparative analysis of binary and ternary cyclodextrin complexes with econazole nitrate in solution and in solid state. Jug M; Mennini N; Kövér KE; Mura P J Pharm Biomed Anal; 2014 Mar; 91():81-91. PubMed ID: 24444785 [TBL] [Abstract][Full Text] [Related]
10. Novel formulation strategies for enhancing oral delivery of methoxyflavones in Kaempferia parviflora by SMEDDS or complexation with 2-hydroxypropyl-β-cyclodextrin. Mekjaruskul C; Yang YT; Leed MG; Sadgrove MP; Jay M; Sripanidkulchai B Int J Pharm; 2013 Mar; 445(1-2):1-11. PubMed ID: 23376503 [TBL] [Abstract][Full Text] [Related]
11. Effects of gastric pH on oral drug absorption: In vitro assessment using a dissolution/permeation system reflecting the gastric dissolution process. Kataoka M; Fukahori M; Ikemura A; Kubota A; Higashino H; Sakuma S; Yamashita S Eur J Pharm Biopharm; 2016 Apr; 101():103-11. PubMed ID: 26873006 [TBL] [Abstract][Full Text] [Related]
12. Impact of amorphization and GI physiology on supersaturation and precipitation of poorly soluble weakly basic drugs using a small-scale in vitro transfer model. Auch C; Jede C; Harms M; Wagner C; Mäder K Int J Pharm; 2020 Jan; 574():118917. PubMed ID: 31811926 [TBL] [Abstract][Full Text] [Related]
13. Influence of hydrophilic polymers on the complexation of carbamazepine with hydroxypropyl-β-cyclodextrin. Medarević D; Kachrimanis K; Djurić Z; Ibrić S Eur J Pharm Sci; 2015 Oct; 78():273-85. PubMed ID: 26255049 [TBL] [Abstract][Full Text] [Related]
14. Analysis of the enhanced oral bioavailability of fenofibrate lipid formulations in fasted humans using an in vitro-in silico-in vivo approach. Fei Y; Kostewicz ES; Sheu MT; Dressman JB Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1274-84. PubMed ID: 23500116 [TBL] [Abstract][Full Text] [Related]
15. Inclusion complexes of tadalafil with natural and chemically modified beta-cyclodextrins. I: preparation and in-vitro evaluation. Badr-Eldin SM; Elkheshen SA; Ghorab MM Eur J Pharm Biopharm; 2008 Nov; 70(3):819-27. PubMed ID: 18655829 [TBL] [Abstract][Full Text] [Related]
16. Precipitation in the small intestine may play a more important role in the in vivo performance of poorly soluble weak bases in the fasted state: case example nelfinavir. Shono Y; Jantratid E; Dressman JB Eur J Pharm Biopharm; 2011 Oct; 79(2):349-56. PubMed ID: 21527341 [TBL] [Abstract][Full Text] [Related]
17. Bioavailability enhancement of poorly water soluble and weakly acidic new chemical entity with 2-hydroxy propyl-beta-cyclodextrin: selection of meglumine, a polyhydroxy base, as a novel ternary component. Basavaraj S; Sihorkar V; Shantha Kumar TR; Sundaramurthi P; Srinivas NR; Venkatesh P; Ramesh M; Kumar Singh S Pharm Dev Technol; 2006; 11(4):443-51. PubMed ID: 17101515 [TBL] [Abstract][Full Text] [Related]
19. Predicting in vivo absorption behavior of oral modified release dosage forms containing pH-dependent poorly soluble drugs using a novel pH-adjusted biphasic in vitro dissolution test. Heigoldt U; Sommer F; Daniels R; Wagner KG Eur J Pharm Biopharm; 2010 Sep; 76(1):105-11. PubMed ID: 20472059 [TBL] [Abstract][Full Text] [Related]
20. Automated small-scale in vitro transfer model as screening tool for the prediction of in vivo-dissolution and precipitation of poorly solubles. Jede C; Wagner C; Kubas H; Weber C; Weigandt M; Koziolek M; Weitschies W Int J Pharm; 2019 Feb; 556():150-158. PubMed ID: 30553006 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]